Synonyms: ACP-2566 | analogue 4 [PMID: 15837309] | Daybue® | glycyl-alpha-methyl-L-prolyl-L-glutamic acid | NNZ-2566 | NNZ2566
trofinetide is an approved drug (FDA (2023))
Compound class:
Peptide or derivative
Comment: Trofinetide (NNZ-2566), a synthetic analogue of the amino‐terminal tripeptide of insulin-like growth factor 1 (IGF-1; GPE). It was developed as a neuroprotective agent, for potential application in neurodegenerative diseases of the central nervous system, and traumatic brain injury.
The endogenous glycine-proline-glutamate tripeptide (GPE, Glypromate) is present in the brain [7], and it has been demonstrated to partially reverse core symptoms in Mecp2-deficient mice that are a model of human Rett syndrome [8]. Trofinetide has been modified to offer a longer half-life than GPE. |
Classification | |
Compound class | Peptide or derivative |
Approved drug? | Yes (FDA (2023)) |
IUPAC Name |
(2S)-2-[[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino]pentanedioic acid |
International Nonproprietary Names | |
INN number | INN |
10076 | trofinetide |
Synonyms |
ACP-2566 | analogue 4 [PMID: 15837309] | Daybue® | glycyl-alpha-methyl-L-prolyl-L-glutamic acid | NNZ-2566 | NNZ2566 |
Database Links | |
CAS Registry No. | 853400-76-7 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL197084 |
DrugBank Ligand | DB06045 |
GtoPdb PubChem SID | 479821272 |
PubChem CID | 11318905 |
Search Google for chemical match using the InChIKey | BUSXWGRAOZQTEY-SDBXPKJASA-N |
Search Google for chemicals with the same backbone | BUSXWGRAOZQTEY |
Search PubMed clinical trials | trofinetide |
Search PubMed titles | trofinetide |
Search PubMed titles/abstracts | trofinetide |
UniChem Compound Search for chemical match using the InChIKey | BUSXWGRAOZQTEY-SDBXPKJASA-N |
UniChem Connectivity Search for chemical match using the InChIKey | BUSXWGRAOZQTEY-SDBXPKJASA-N |